MANNKIND CORP MNKD
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-11.89
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $349.0M | $5.9M | — | $13.7M | -$51.0M |
| 2024 | $285.5M | $27.6M | — | $32.8M | -$78.8M |
| 2023 | $199.0M | -$11.9M | — | -$8.3M | -$246.2M |
| 2022 | $99.8M | -$87.4M | — | -$88.3M | -$250.5M |
| 2021 | $75.4M | -$80.9M | — | -$73.2M | -$209.3M |
| 2020 | $65.1M | -$57.2M | — | -$28.9M | -$180.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Consiglio Ronald J | director | 2026-05-20 | Grant | 10,000 | $2.95 |
| Tross Stuart A | Chief People & Workpl Officer | 2026-05-20 | Grant | 33,898 | $2.95 |
| Marasco Dominic | Pres, Endocrine Business Unit | 2026-05-20 | Grant | 8,474 | $2.95 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -11.89 (distress)
- Working capital / assets 0.152
- Retained earnings / assets -4.034
- EBIT / assets 0.049
- Equity / liabilities -0.061
Source: SEC EDGAR filings · CIK 0000899460 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.